Duke University

Ohio State Innovation Foundation

Shahid M Nimjee

Bruce A Sullenger

Juliana Layzer

Sabah Oney

George A Pitoc

Nanette Que-Gewirth

Provided herein are aptamers capable of inhibiting the activity of Von Willebrand Factor (VWF). Pharmaceutical compositions comprising these aptamers are also provided. Methods of preventing blood clot formation in a subject by administering the aptamers are provided and methods of treating a blood clot by administering a VWF-targeting agent are also provided.

Von Willebrand Factor (VWF)-targeting agents and methods of using the same

Von Willebrand Factor (VWF)&#x2014;targeting agents and methods of using the same

The present invention relates, in general, to receptors and to platelet aggregation and, in particular, to a method of inhibiting platelet aggregation using an aptamer that binds to and inhibits the activity of a receptor, such as glycoprotein IIb/IIIa (gpIIb/IIIa), and to aptamers suitable for use in such a method. The invention also relates to antidotes to antiplatelet agents and to methods of using such antidotes to reverse aptamer-induced platelet inhibition. The invention further relates to von Willebrand Factor (VWF) inhibitors, and antidotes therefore, and to methods of using same.

Reversible platelet inhibition

Growing community of inventors

Columbus, OH, United States of America

Shahid M Nimjee